Cortechs.ai | NeuroQuant Brain Tumor

FDA-cleared software for advanced brain tumor analyses

Powered by Al, NeuroQuant® Brain Tumor assists radiologists, oncologists, neurosurgeons, and the Tumor Board by providing objective quantification and analysis of tumor changes over time

Cortechs.ai|NeuroQuant Brain Tumor

Comprehensive Brain Tumor Analysis

Cortechs.ai|NeuroQuant Brain Tumor

Advanced classification and segmentation of both high-grade and low-grade gliomas in pre- and postoperative studies. Our AI analyzes regions of interest including the necrotic core, enhancing tumor tissue, surrounding FLAIR hyperintensity, and resection cavity.

Required sequences: T1 pre, T1 post, T2, and T2 FLAIR

Cortechs.ai|NeuroQuant Brain Tumor

Designed for both single- and multi-timepoint studies, this module classifies and tracks brain metastases over time. It analyzes new, enlarging, shrinking, stable, and resolved lesions with comprehensive output including lesion count, individual and total volumetrics, and precise lesion location.

Required sequences: T1 pre and T1 post

Cortechs.ai|NeuroQuant Brain Tumor

Supports both single- and multi-timepoint analysis of meningiomas. The system segments the necrotic core and enhancing tissue, providing detailed volumetric data for current, prior, and interval change analysis.

Required sequences: T1 pre and T1 post

Objective Tumor Insights Made Simple

Cortechs.ai|NeuroQuant Brain Tumor

Segmentation & Volumetrics Report

Detailed volumes of tumor regions are provided in comprehensive reports and automatically routed to PACS for seamless integration into your workflow.

Cortechs.ai|NeuroQuant Brain Tumor

Longitudinal Analysis

Prior studies of the same patients are automatically included on reports for precise volumetric comparison over time, enabling better treatment monitoring.

Cortechs.ai|NeuroQuant Brain Tumor

Tumor Segmentation Color Overlay Series

Slice-by-slice tumor segmentations are routed to PACS with tumor regions of interest color coded for easy viewing and interpretation.

Cortechs.ai|NeuroQuant Brain Tumor

RT STRUCT

Advanced contour generation that can be manipulated for treatment planning, surgical planning, and radiation oncology applications.

NeuroQuant® Brain Tumor Benefits

Cortechs.ai|NeuroQuant Brain Tumor

Enhanced Objectivity & Reproducibility

Quantitative brain tumor volumetrics provide more objectivity and are more reproducible than 2D visual analyses ¹

¹ Blomstergen et al., (2018, July)

Cortechs.ai|NeuroQuant Brain Tumor

Time-Series Analysis

Displays time-series data for tumor volumes across multiple scans, allowing for better comparison and treatment planning

Cortechs.ai|NeuroQuant Brain Tumor

Comprehensive Tumor Coverage

Supports the analysis of gliomas, metastases, and meningiomas, offering broader clinical utility than solutions limited to one tumor type

NeuroQuant® Brain Tumor Reports

Comprehensive segmentation and volumetrics reporting, automatically routed to PACS.

Cortechs.ai|NeuroQuant Brain Tumor

Understanding CPT Codes 0865T & 0866T

As of January 1, 2024, new Category III CPT codes (0865T, 0866T) are active for AI-assisted quantitative brain MRI analysis. These codes apply to a variety of vendor solutions, including Cortechs.ai, and serve as an essential step toward achieving permanent reimbursement.

Related insights

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

02/02/2025

NeuroQuant® Brain Tumor: Revolutionizing Neuro-Oncology with AI-Driven Precision

Dr. Suzie Bash and Dr. Jeff Rudie dive deep into the advanced functionalities and clinical benefits of the tool that is revolutionizing neuro-oncology
Scroll to Top